What Happened?
Hamilton, AK-based Fusion Pharmaceuticals Appointed Scott Hofmann as Stability Associate
About the Company
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion`s lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.
About the Person
Scott Hofmann is Stability Associate at Fusion Pharmaceuticals. Previously, Scott held various senior HR leadership roles in the industry.
Info Source
News
Short Profile